PMID- 24141626
OWN - NLM
STAT- MEDLINE
DCOM- 20140826
LR  - 20211021
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 19
IP  - 24
DP  - 2013 Dec 15
TI  - Prognostic significance of pretreatment serum cytokines in classical Hodgkin 
      lymphoma.
PG  - 6812-9
LID - 10.1158/1078-0432.CCR-13-1879 [doi]
AB  - PURPOSE: Although the International Prognostic Score (IPS) is the gold standard 
      for risk-stratifying patients with classical Hodgkin lymphoma (cHL), these 
      criteria do not accurately predict outcome. As cytokines are critically involved 
      in driving cHL, we tested whether pretreatment serum cytokine levels could 
      provide additional prognostic information. EXPERIMENTAL DESIGN: Thirty cytokines 
      were measured in pretreatment serum from 140 patients with cHL and compared with 
      50 nonlymphoma controls. Patients were followed for event-free survival (EFS) and 
      overall survival (OS), and Cox proportional hazards regression models were used 
      to assess the association of individual cytokines and the cytokine profiles with 
      outcome via unadjusted and IPS-adjusted HR. RESULTS: Twelve cytokines (EGF, bFGF, 
      G-CSF, HGF, IL-6, IL-8, IL-12, IL-2R, IP-10, MIG, TNF-alpha, and VEGF) were 
      significantly (P < 0.05) higher in patients with cHL than controls; elevated 
      levels of HGF, IL-6, IL-2R, IP-10, and MIG were all associated with poorer EFS. 
      Only interleukin-2 receptor (IL-2R; P = 0.002) and interleukin (IL)-6 (P < 0.001) 
      were independently prognostic. Patients with increased IL-6 and IL-2R had a 
      significantly higher risk of early relapse and death, a finding that remained 
      significant even after IPS-based risk stratification. Although elevated IL-6 and 
      IL-2R correlated with the IPS, soluble CD30 (sCD30), and thymus and 
      activation-related chemokine (TARC) levels, the two-cytokine model remained 
      independently predictive of prognosis. CONCLUSIONS: Elevated pretreatment serum 
      cytokines are associated with increased disease relapse and inferior survival in 
      cHL. Thus, the pretreatment cytokine profile, particularly serum levels of IL-6 
      and IL-2R, may be used to identify patients with cHL at high risk for 
      early-disease relapse.
CI  - (c)2013 AACR.
FAU - Marri, Preethi Reddy
AU  - Marri PR
AD  - Authors' Affiliations: Divisions of Hematology and Biomedical Statistics and 
      Informatics, Mayo Clinic, Rochester, Minnesota; and Department of Internal 
      Medicine, College of Medicine, University of Iowa, Iowa City, Iowa.
FAU - Hodge, Lucy S
AU  - Hodge LS
FAU - Maurer, Matthew J
AU  - Maurer MJ
FAU - Ziesmer, Steven C
AU  - Ziesmer SC
FAU - Slager, Susan L
AU  - Slager SL
FAU - Habermann, Thomas M
AU  - Habermann TM
FAU - Link, Brian K
AU  - Link BK
FAU - Cerhan, James R
AU  - Cerhan JR
FAU - Novak, Anne J
AU  - Novak AJ
FAU - Ansell, Stephen M
AU  - Ansell SM
LA  - eng
GR  - P30 CA015083/CA/NCI NIH HHS/United States
GR  - P50 CA097274/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20131018
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Interleukin-6)
RN  - 0 (Receptors, Interleukin-2)
SB  - IM
CIN - Clin Cancer Res. 2014 Dec 15;20(24):6633. PMID: 25512637
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Hodgkin Disease/*blood/pathology/therapy
MH  - Humans
MH  - Interleukin-6/*blood
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*blood/pathology/therapy
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Receptors, Interleukin-2/*blood
PMC - PMC3867576
MID - NIHMS534086
EDAT- 2013/10/22 06:00
MHDA- 2014/08/27 06:00
PMCR- 2014/12/15
CRDT- 2013/10/22 06:00
PHST- 2013/10/22 06:00 [entrez]
PHST- 2013/10/22 06:00 [pubmed]
PHST- 2014/08/27 06:00 [medline]
PHST- 2014/12/15 00:00 [pmc-release]
AID - 1078-0432.CCR-13-1879 [pii]
AID - 10.1158/1078-0432.CCR-13-1879 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2013 Dec 15;19(24):6812-9. doi: 10.1158/1078-0432.CCR-13-1879. 
      Epub 2013 Oct 18.